AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab
Description: Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
Study NCT02947685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
Study NCT03959878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant Pressure Skin Disk
Description: The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
Study NCT04203030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
Study NCT05019469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmic vibration cueing (lower leg)
Description: A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
Study NCT01126736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
Study NCT01126736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
Study NCT01126736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (eribulin; E7389)
Description: Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
Study NCT01371162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5428029
Description: Multiple ascending doses
Study NCT01072344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile (Matricaria recutita)
Description: 500 mg 3 times daily
Study NCT01072344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chamomile (Matricaria recutita)
Description: 500 mg 3 times daily
Study NCT04285385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Description: 0.10 ml of lavender essential oil
Study NCT04285385 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham aromatherapy
Description: 0.10 ml of mineral oil
Study NCT00599807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
Study NCT02160405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: native potato
Study NCT01567098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single incision laparoscopic appendectomy
Description: performing appendectomy through a single incision in the abdomen
Study NCT01567098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision laparoscopic appendectomy
Description: performing appendectomy through a single incision in the abdomen
Study NCT02668146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Study drug will be administered to study subjects
Study NCT02668146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to study subjects
Study NCT05911100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirography and assessment of pulmonary diffusion capacity
Description: Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
Study NCT05911100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary stress test
Description: The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
Study NCT05911100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography of the chest organs
Description: CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department.
Study NCT05911100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart echocardiography
Description: It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
Study NCT05911100 — intervention group
Intervention type: OTHER
Intervention: SF-36 Quality of Life Questionnaire
Description: https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
Study NCT05911100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Demographic and antropometric measures
Description: Age, sex, height. weight, body mass index (BMI)
Study NCT05911100 — intervention group
Intervention type: OTHER
Intervention: Indicators characterizing the severity of the underlying disease
Description: * Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~* Medications taken.
Study NCT02605642 — intervention group
Intervention type: DRUG
Intervention: CT-P13
Description: biosimilar infliximab
Study NCT01745640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POMALIDOMIDE
Description: hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
Study NCT01745640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
Study NCT02584491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional gait-related training
Description: The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
Study NCT00235131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Stent
Description: Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
Study NCT00235131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Luminexx Stent
Description: Bard® Luminexx™ 6F Vascular Stent
Study NCT01371162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple doses
Study NCT00746967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sildenafil
Description: sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
Study NCT02111564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 10 mg
Description: Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
Study NCT02111564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 7.5 mg
Description: Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from >=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
Study NCT02111564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
Study NCT02592889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MITRACLIP
Description: MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
Study NCT03459027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g) acutely
Study NCT03459027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Super Beets
Description: Nitrate rich beetroot powder (10g) acutely
Study NCT03459027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot powder
Description: Nitrate devoid beetroot powder (10g) acutely
Study NCT03459027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot powder
Description: Nitrate devoid beetroot powder (10g) acutely
Study NCT03018886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GHRH plus arginine test
Description: One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
Study NCT03018886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GHRH plus arginine test
Description: One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
Study NCT02488304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HRCT scans
Description: A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2.
Study NCT02761083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novosyn® Quick
Description: Eye surgery
Study NCT02761083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl® Rapid
Description: Eye surgery
Study NCT02135731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review software with pictures
Description: The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
Study NCT00391404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg weekly (oral)
Study NCT00391404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00388050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice decision aid
Description: The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
Study NCT01286961 — intervention group
Intervention type: DRUG
Intervention: bowel preparation using split dose of polyethylene glycol
Description: polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
Study NCT00605956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatrOVA Creme Rinse - 1%
Description: NatrOVA Creme Rinse - 1% spinosad
Study NCT00605956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatrOVA Creme Rinse Vehicle Only
Description: NatrOVA Creme Rinse Vehicle - no spinosad
Study NCT00605956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blank Patch
Description: Blank Patch
Study NCT00095147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Description: Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
Study NCT00095147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab (INF) + MTX, DB
Description: Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
Study NCT00388050 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
Study NCT00095147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA) + MTX, DB
Description: Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
Study NCT00095147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLA + MTX switched to ABA+ MTX, DB
Description: Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
Study NCT00095147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABA, open-label (OL)
Description: Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
Study NCT00470509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 2 subcutaneous injections on day 0 and 7
Study NCT00470509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 2 subcutaneous injections on day 0 and 7
Study NCT00865384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study NCT00865384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON® 15 mg tablets, single dose
Description: B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
Study NCT00319969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 40mg/m\<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study NCT01812447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Description: Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
Study NCT01812447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
Study NCT00319969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.5mg/m\<2> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.